Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

The Role of Autoreactive B Cells in Rheumatoid Arthritis

Catherine Kolonko  |  September 17, 2019

The body uses B cells to produce antibodies that can fight off infection by invading antigens and bacteria. But in rheumatoid arthritis (RA), the immune system produces autoantibodies that work against the body’s proteins to attack joint tissues. Researchers believe this process is helped along by autoreactive B cells that live in bone matter and…

Catch Your Breath: Insights into ILD in RA Patients

Jason Liebowitz, MD, FACR  |  September 12, 2019

Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…

No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 9, 2019

Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…

Long-Term Physical Activity Lowers the Risk of RA among Women

Arthritis & Rheumatology  |  August 27, 2019

A new study adds to the evidence that metabolic factors play an important role in the pathogenesis of rheumatoid arthritis (RA). In this large, prospective cohort study, Liu et al. found that increased physical activity among women was associated with a reduced risk of RA…

Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

Nitasha Kumar, MD  |  August 16, 2019

Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  August 16, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Asthma, Allergic Disease, Passive Smoke Exposure & the Risk of RA

Arthritis & Rheumatology  |  August 7, 2019

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. One hypothesis is that inflammation in the respiratory tract results in autoantibody formation that later leads to disease. Kronzer et al. set out to narrow the knowledge gaps related to the oral-respiratory factors that may mediate RA pathogenesis.

A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes

Arthritis Care & Research  |  August 2, 2019

Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…

RheumPAC Advocates for Department of Defense Arthritis Research Funding

Matt Baker, MD, MS  |  August 1, 2019

The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.

The Prevalence, Incidence, Mortality & Costs of RA-Related ILD

Kurt Ullman  |  July 18, 2019

Interstitial lung disease (ILD) can be associated with rheumatoid arthritis (RA) with significant morbidity and mortality. An article in The Journal of Rheumatology focused on calculating the prevalence, incidence, mortality and costs to the healthcare system of RA-related ILD (RA-ILD).1 “RA is the most common of connective tissue diseases encountered by rheuma­tologists—affecting about 1% of…

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences